Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids

Qingguo Li1,2†, Huizhen Sun3,4†, Dakui Luo1,2†, Lu Gan5†, Shaobo Mo1,2, Weixing Dai1,2, Lei Liang1,2, Yufei Yang1,2, Midie Xu2,6, Jing Li7, Peiyong Zheng8, Xinxiang Li1,2*, Yan Li9* and Ziliang Wang3*

Abstract

Background: Resistance to oxaliplatin is a major obstacle for the management of locally advanced and metastatic colon cancer (CC). Although long noncoding RNAs (lncRNAs) play key roles in CC, the relationships between lncRNAs and resistance to oxaliplatin have been poorly understood yet.

Methods: Chemo-sensitive and chemo-resistant organoids were established from colon cancer tissues of the oxaliplatin-sensitive or -resistant patients. Analysis of the patient cohort indicated that lnc-RP11-536 K7.3 had a potential oncogenic role in CC. Further, a series of functional in vitro and in vivo experiments were conducted to assess the effects of lnc-RP11-536 K7.3 on CC proliferation, glycolysis, and angiogenesis. RNA pull-down assay, luciferase reporter and fluorescent in situ hybridization assays were used to confirm the interactions between lnc-RP11-536 K7.3, SOX2 and their downstream target HIF-1α.

Results: In this study, we identified a novel lncRNA, lnc-RP11-536 K7.3, was associated with resistance to oxaliplatin and predicted a poor survival. Knockout of lnc-RP11-536 K7.3 inhibited the proliferation, glycolysis, and angiogenesis, whereas enhanced chemosensitivity in chemo-resistant organoids and CC cells both in vitro and in vivo. Furthermore, we found that lnc-RP11-536 K7.3 recruited SOX2 to transcriptionally activate USP7 mRNA expression. The accumulative USP7 resulted in deubiquitylation and stabilization of HIF-1α, thereby facilitating resistance to oxaliplatin.

Conclusion: In conclusion, our findings indicated that lnc-RP11-536 K7.3 could promote proliferation, glycolysis, angiogenesis, and chemo-resistance in CC by SOX2/USP7/HIF-1α signaling axis. This revealed a new insight into how lncRNA could regulate chemosensitivity and provide a potential therapeutic target for reversing resistance to oxaliplatin in the management of CC.

Keywords: Lnc-RP11-536 K7.3, Organoid, Oxaliplatin, Colon cancer

*Correspondence: xinxiangli@fudan.edu.cn; liy33@sustech.edu.cn; huf_zlwang@126.com
†Qingguo Li, Huizhen Sun, Dakui Luo and Lu Gan contributed equally to this work.
1 Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai 200032, China
3 Clinical Medicine Transformation Center and Office of Academic Research, Shanghai Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China
9 Department of Biology, Southern University of Science and Technology, 1088 Xueyuan Blvd., Nanshan District, Shenzhen 518055, China

Full list of author information is available at the end of the article
Background
Colon cancer (CC) is the fifth most common malignancy and the fifth leading cause of cancer-related mortality among 36 types of cancer worldwide [1]. Oxaliplatin-based chemotherapy is recommended for locally advanced or metastatic CC [2, 3]. Acquisition of resistance to chemotherapy results in therapy failure and disease progression in a number of CC patients. Great efforts have been dedicated to reveal the mechanism of resistance acquisition of oxaliplatin and propose some interventional strategies [4, 5]. However, the cause of resistance acquisition of oxaliplatin remains elusive. A limited number of prognostic factors have been developed and validated as predictive biomarkers or therapeutic targets [6–9]. Thus, it is highly essential to elucidate the precise mechanisms of resistance to oxaliplatin, identify effective biomarkers for predicting oxaliplatin response, and develop targeted therapies for minimizing resistance to oxaliplatin in CC patients.

Long non-coding RNAs (lncRNAs) are RNA molecules, which are longer than 200 nucleotides without a protein coding potential. Emerging evidence has indicated that lncRNAs play significant roles in multiple physiological and pathological processes by distinctive mechanisms [10, 11]. Notably, aberrant expression of lncRNAs has been reported in diverse types of cancer and dysregulation of lncRNAs participates in tumorigenesis and chemotherapy resistance [12–14]. However, the influences of lncRNAs on resistance to oxaliplatin have been poorly understood. In the present study, we established oxaliplatin-resistant and -sensitive organoids derived from CC patients to identify an oxaliplatin-resistant related lncRNA, namely lnc-RP11-536 K7.3. Functions and mechanisms of lnc-RP11-536 K7.3 were further dissected in CC. Our findings demonstrated that lnc-RP11-536 K7.3 could participate in resistance to oxaliplatin and could be a promising therapeutic target for chemosensitization in CC.

Materials and methods

Patients and tissue samples
Tissue microarrays were collected from patients with CC who were admitted to Fudan University Shanghai Cancer Center (FUSCC; Shanghai, China) from 2007 to 2009. Clinical data are summarized in Supplementary Table S1. Overall survival (OS) was measured as the length of time from initiation of surgery to death from any cause or the most recent follow-up. Progression-free survival (PFS) was calculated from the date of surgery to occurrence of progression or relapse. PFS less than 6 months was defined as resistant to the last chemotherapy; otherwise, it was defined as sensitive to the last chemotherapy.

Collection and culture of organoids
Chemo-sensitive organoids in our study were collected from chemo-sensitive patients’ CC tissues in the first surgery. The chemo-resistant organoids were gained from CC patients, who underwent reoperation after failure of oxaliplatin-based chemotherapy. Then, the organoids were cultured as described below and drug-resistance testing was performed with oxaliplatin the treatment for 25 days.

After that, fresh tumor tissues were immediately cultured in advanced Dulbecco’s modified Eagle’s medium (DMEM)/F12 supplemented with 1% penicillin streptomycin. Tissues were diced into approximately 2–3-mm sections, and then, digested at 37 °C for 1 h by trypsin. The digested tissues were filtered through a 70-μm filter (catalog number: 352350; Falcon, San Diego, CA, USA). The cell suspension was then spun at 1000rpm for 5 min to create a cell pellet. The pellet was washed with red blood for 2–3 times. Cells in solid tumor were then mixed with growth factor reduced Matrigel (catalog number: 352350; Falcon, San Diego, CA, USA). The cell suspension was then spun at 1000rpm for 5 min to create a cell pellet. The pellet was washed with red blood for 2–3 times. Cells in solid tumor were then mixed with growth factor reduced Matrigel (catalog number: CB-40230C; Corning, New York, NY, USA), and cellular concentration was set to 10,000–20,000 cells/50 μL. Once the Matrigel was solidified, 500 μL of general (DMEM)/F12 culture medium was added. Patient-derived organoids (PDOs) were kept in a humidified atmosphere of (See figure on next page.)

Fig. 1 InRP11-536 K7.3 was highly expressed in oxaliplatin-resistant organoids of CC patients. A Circos plot displaying the distribution and expression of lncRNAs on human chromosomes. The outermost layer was a chromosome map of the human genome. The inner circles from outside to inside were corresponded to distribution and expression of detected lncRNAs on the chromosomes, distribution and expression of significantly expressed lncRNAs, and predicted mRNAs sponged by significantly expressed lncRNAs, respectively. B Differentially expressed lncRNAs between 3 oxaliplatin-resistant and 3-sensitive organoids. C Differential expression of inRP11-536 K7.3 in 22 oxaliplatin-resistant and 22-sensitive organoids of CC patients detected by qPCR. The experiment was repeated 3 times. D Fluorescence in situ hybridization (FISH) assay of lnc-RP11-536 K7.3 in 22 oxaliplatin-resistant and 22-sensitive organoids of CC patients. E Kaplan-Meier plot of disease free survival (DFS) according to lnc-RP11-536 K7.3 expression. Data were obtained from Shanghai Cancer Center. F Kaplan-Meier plot of overall survival (OS) according to lnc-RP11-536 K7.3 expression. Data were obtained from Shanghai Cancer Center. G qRT-PCR assay was used to detect the efficacy of lnc-RP11-536 K7.3 knockout in oxaliplatin-resistant organoids. The experiment was repeated 3 times. H Gene ontology of mass spectrum analysis in oxaliplatin-resistant and -sensitive colon cancer organoids. I Pathway examination of mass spectrum analysis in oxaliplatin-resistant and -sensitive colon cancer organoids.
Fig. 1 (See legend on previous page.)
Knockout of lnc-RP11-536K7.3 increased chemosensitivity in chemo-resistant organoids and cells in CC patients. A Chemo-resistant RKO (CR-RKO) cell line was generated by gradual increase of oxaliplatin concentration. CCK8 assay showed that IC50 value of CR-RKO cells was much higher than that of the parental RKO cells (**P < 0.01). B qRT-PCR assay was used to detect the efficacy of lnc-RP11-536K7.3 knockout in CR-RKO cell lines. C Cell viability assay of organoids treated with or without 1 μM oxaliplatin in different time intervals. D IC50 values of oxaliplatin. Lnc-RP11-536K7.3-knockout and control cells were treated with different concentrations of oxaliplatin for 48 h (**P < 0.01). E-H Colony formation efficiency of chemo-resistant CC organoids and cells treated with or without 2 μM oxaliplatin for 7 days. Represent pictures in chemo-resistant CC organoids (E) and chemo-resistant RKO cells (F). Statistical analysis of relative colony formation in chemo-resistant CC organoids (G) and chemo-resistant RKO cells (H) (**P < 0.01). Above experiments were repeated 3 times.
5% CO₂ and 95% air at 37°C, and medium was changed every 2~3 days. The splitting ratio was 1:3.

**Statistical analysis**

Data were statistically analyzed by using GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA) and presented as mean ± SD. Comparisons between control and treatment groups were performed via the paired t-test or one-way analysis of variance (ANOVA), followed by Tukey multiple comparison tests. Clinicopathological data were analyzed using SPSS 24.0 software (IBM, Armonk, NY, USA). The Kaplan–Meier method and the log-rank test were employed to estimate OS. Variables with P-values < 0.05 in univariate analysis were included in subsequent multivariate analyses based on the Cox proportional-hazards model. A probability with value of less than 0.05 was considered statistically significant.

See online supplementary section for detailed explanation on methods.

**Results**

**Lnc-RP11-536 K7.3 was highly expressed in oxaliplatin-resistant organoids of CC patients and predicted worse prognosis**

In order to investigate mechanisms of resistance to oxaliplatin through a model with a superior genetic and phenotypic recapitulation, chemo-resistant and -sensitive organoids derived from CC patients were established. Representative images of hematoxylin-eosin (HE) staining of oxaliplatin-resistant and -sensitive human CC tissues are shown in Fig. S1A. As expected, oxaliplatin significantly inhibited the growth of oxaliplatin-resistant organoid, whereas it slightly influenced oxaliplatin-resistant organoids (Fig. S1B-C). Representative images of HE staining of oxaliplatin-resistant and -sensitive organoids of human CC tissues are displayed in Fig. S1D. IHC revealed that the expressions of CK20 and β-catenin were higher in oxaliplatin-resistant organoids compared with oxaliplatin-sensitive organoids, indicating that oxaliplatin-resistant organoids behaved more aggressively (Fig. S1E). Consistently, the expressions of CK20 and β-catenin were higher in oxaliplatin-resistant human CC tissues compared with oxaliplatin-sensitive human CC tissues (Fig. S2A).

To gain a deep insight into the molecular mechanism and dysregulated pathways of oxaliplatin resistance, genome-wide analysis of IncRNA expression was carried out in 3 oxaliplatin-resistant and 3 -sensitive organoids of CC patients. Circos plot was employed to display distribution and expression of IncRNAs on human chromosomes (Fig. 1A). It was found that Inc-RP11-536 K7.3 was among the most significantly differentially expressed IncRNAs in the two groups (Fig. 1B). Then, we confirmed that Inc-RP11-536 K7.3 was up-regulated in oxaliplatin-resistant organoids compared with oxaliplatin-sensitive organoids by qRT-PCR analysis (Fig. 1C). Fluorescence in situ hybridization (FISH) assay further approved that Inc-RP11-536 K7.3 was mainly expressed in oxaliplatin-resistant organoids of CC patients (Fig. 1D). We also evaluated the expression of Inc-RP11-536 K7.3 in Tissue microarray (TMA) consisting of 276 patients. High expression of Inc-RP11-536 K7.3 was detected in 67.75% of the patients (Table S1). Kaplan-Meier survival analysis revealed that significantly shorter overall survival (OS) and disease-free survival (DFS) were associated with high expression of Inc-RP11-536 K7.3 in CC patients (Fig. 1E-F). Subsequently, we also found that the expression of Inc-RP11-536 K7.3 was up-regulated in different cancer tissues compared with adjacent non-tumor tissues using data acquired from The Cancer Genome Atlas (TCGA) and high expression of Inc-RP11-536 K7.3 predicted a poor prognosis (Fig. S2B-C). We selected three oxaliplatin-resistant organoids to knockout expression of Inc-RP11-536 K7.3 for further analysis (Fig. 1G). Using Gene Ontology (GO) analysis, we found that the genes associated with resistance to oxaliplatin resulted by the knockout of Inc-RP11-536 K7.3 were enriched in metabolic process, ubiquitin-mediated proteolysis, and angiogenesis (Fig. 1H). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis also revealed that ubiquitin-mediated proteolysis, carbon metabolism, and vascular endothelial growth factor (VEGF) signaling pathway were involved in resistance to oxaliplatin (Fig. 1I).
Fig. 3 (See legend on previous page.)
Silencing of Inc-RP11-536 K7.3 repressed resistance to oxaliplatin in CC samples

Using patient-derived organoids and drug-resistant tumor cell line models, we attempted to determine the influence of Inc-RP11-536 K7.3 on resistance to oxaliplatin in a robust manner. Oxaliplatin-resistant RKO (CR-RKO: Chemo-resistant RKO) CC cell line was established by treating cells with increasing concentrations of oxaliplatin. Compared with parental cells, CR-RKO cells responded poorly to oxaliplatin, as evidenced by an increased half maximal inhibitory concentration (IC50) value (Fig. 2A). We then knocked out the expression of Inc-RP11-536 K7.3 in CR-RKO cells to examine its role in cell viability (Fig. 2B). Through CCK-8 assay we discovered that depletion of Inc-RP11-536 K7.3 significantly decreased viability of oxaliplatin-resistant CC organoids and increased sensitivity to oxaliplatin treatment in models of organoids and cells (Fig. 2C-D). Subsequent colony formation efficiency of chemo-resistant CC organoids and CR-RKO cells was also obviously reduced after silencing of Inc-RP11-536 K7.3 (Fig. 2E-H). Intriguingly, the suppressive effects of Inc-RP11-536 K7.3 depletion on colony formation were markedly more evident under oxaliplatin treatment, suggesting that oxaliplatin resistant CC cells were associated with Inc-PR11-536 K7.3 expression. Above results indicated that Inc-RP11-536 K7.3 induced resistance to oxaliplatin in CC.

Lnc-RP11-536 K7.3 increased glycolysis and angiogenesis in CC

In the current study, proteomic analysis of organoids revealed that glycolysis and angiogenesis were closely correlated with chemo-resistance [15]. Therefore, we determined whether Inc-RP11-536 K7.3 could regulate glycolysis in chemo-resistant CC organoids and cells. Lnc-RP11-536 K7.3 depletion decreased glycolysis and mitochondrial oxidative phosphorylationin chemo-resistant CC organoids and cells, as evidenced by a reduced glucose uptake, ATP, nicotinamide adenine dinucleotide phosphate (NADPH), ECAR, and OCR (Fig. 3A-J). We further examined whether the inhibition of glycolysis could mimic the role of Inc-RP11-536 K7.3 depletion in oxaliplatin resistance. As expected, 2-deoxyglucose, a glycolytic inhibitor, diminished resistance to oxaliplatin and decreased IC50 of oxaliplatin (Fig. 3K-M). In addition to glycolysis, we also investigated the role of Inc-RP11-536 K7.3 knockout in angiogenesis. Human umbilical vein endothelial cells (HUVEC) cultured in the conditional medium of Inc-RP11-536 K7.3-depleted CR-RKO cells formed significantly less tubes (Fig. 3N-O). Moreover, we constructed Inc-RP11-536 K7.3 overexpressed CC organoids and cells in the Inc-RP11-536 K7.3 depleted organoids and cells, and found that Inc-RP11-536 K7.3 overexpression effectively reversed the decrease of glycolysis level and tube formation induced by Inc-RP11-536 K7.3 knockout (Fig. S3A-G).

Lnc-RP11-536 K7.3 recruited SOX2 to transcriptionally activate deubiquitinase USP7 and subsequently enhanced HIF-1α stability

In order to interrogate the activity and mechanism of Inc-RP11-536 K7.3, we performed high-throughput RNA sequencing on Inc-RP11-536 K7.3 knocked out organoids. It was noted that IncRNAs could influence the expressions of neighboring genes [16]. As no neighboring genes were detected with differential expression, we postulated that Inc-RP11-536 K7.3 might execute functions in the transcriptional level. To determine the downstream target of Inc-RP11-536 K7.3, we compared the expression profile between Inc-RP11-536 K7.3 knocked out organoids and control group, which revealed that USP7 was positively correlated with Inc-RP11-536 K7.3 expression at mRNA level (Fig. 4A). Besides, the results of qRT-PCR assay found that lnc-RP11-536 K7.3 depletion resulted in a notable downregulation of USP7 (Fig. 4B). Luciferase reporter assay also indicated that USP7 promoter activity was affected by the knockout of Inc-RP11-536 K7.3 (Fig. 4C). The above results indicated
Fig. 4 (See legend on previous page.)
that lnc-RP11-536 K7.3 might increase the expression of USP7 by enhancing the activity of USP7 promoter.

To explore the underlying regulatory mechanism of lnc-RP11-536 K7.3 on the promoter activity of USP7, we conducted RNA pull-down assay and mass spectrometry analysis to search for the potential mediators binding to lnc-RP11-536 K7.3 using chemo-resistant CC organoids. The results indicated that lnc-RP11-536 K7.3 specifically pulled down SOX2 protein (Fig. 4D). Furthermore, RIP assay was conducted to validate this finding and found a remarkable enrichment of lnc-RP11-536 K7.3 using an anti-SOX2 antibody compared with using IgG (Fig. 4E).

These results indicated that lnc-RP11-536 K7.3 interacted with the SOX2 protein. FISH and immunofluorescence assay showed that the expression level of SOX2 was positively associated with that of lnc-RP11-536 K7.3 in chemo-resistant CC organoids and CR-RKO cell lines (Fig. 4F). Moreover, the enhanced expression of SOX2 could significantly increase cell viability inhibition induced by lnc-RP11-536 K7.3 depletion in chemo-resistant CC organoids, as well as IC50 of chemo-resistant cells upon oxaliplatin treatment (Fig. S4A-B). Similarly, overexpression of SOX2 partially counteracted the inhibitory effect of lnc-RP11-536 K7.3 depletion on colony formation efficiency in both chemo-resistant CC organoids and CR-RKO cell lines treated with or without oxaliplatin (Fig. S4C). Additionally, overexpression of SOX2 partially neutralized the inhibitory effect of lnc-RP11-536 K7.3 depletion on glycolysis in chemo-resistant CC organoids and CR-RKO cell lines (Fig. S4D-F).

By the analysis of RNA-Sequencing assay, we found that deubiquitinating enzyme USP7 was a potential target gene of SOX2. To confirm the exact region within the USP7 promoter that SOX2 binds, we performed ChIP assays and identified two SOX2 binding sites existed at approximately 900–1500 bp upstream of the open reading frame of USP7. (Fig. 4G-I) Mutation of each SOX2 binding motif abrogated its transcriptional regulation on USP7 (Fig. 4J-K). qRT-PCR assay revealed that lnc-RP11-536 K7.3 depletion resulted in a notable downregulation of USP7 while overexpression of SOX2 reversed the inhibitory effect of lnc-RP11-536 K7.3 depletion on USP7 (Fig. 4L). Coexistence of lnc-RP11-536 K7.3 strengthened the binding of SOX2 to USP7, indicating that interaction between lnc-RP11-536 K7.3 and SOX2 has a synergetic effect on USP7 activation (Fig. 4M). Luciferase reporter assay also indicated that the overexpression of SOX2 reversed the effect of knockout of lnc-RP11-536 K7.3 on USP7 activity (Fig. 4N). These results suggested that lnc-RP11-536 K7.3 can recruit SOX2 to regulate the promoter activity of USP7.

To further explore putative substrates of USP7, we generated HEK293T cells overexpressing HA-USP7 to perform immunoprecipitation (IP) and mass spectrometry analysis and found that HIF-1α was a potential USP7-interacting protein (Fig. 5A). As expected, the expressions of USP7 and HIF-1α exhibited a consistent trend, with reduced expression levels in lnc-RP11-536 K7.3 knocked out organoids and CR-RKO cell lines (Fig. 5B). Co-IP assay further revealed that USP7 primarily interacted with HIF-1α (Fig. 5C). In support of a role of USP7 in regulating HIF-1α stability, the half-life of HIF-1α was markedly shortened upon downregulation of USP7 using shRNA (Fig. 5D). Furthermore, we found that co-transfection USP7 specifically decreased ubiquitination of HIF-1α, while co-transfection of shRNAs targeting USP7 promoted ubiquitination of HIF-1α (Fig. 5E, H). As expected, ectopically expressed USP7 decreased ubiquitination of endogenous HIF-1α, while depletion of USP7 promoted ubiquitination of endogenous HIF-1α (Fig. 5F-G). These studies further suggested that HIF-1α is a possible physiologic substrate of USP7. Depletion of

**Fig. 5** lnc-RP11-536 K7.3 combined with SOX2 to modulate HIF-1α stability by USP7. A Immunoprecipitation and mass spectrometry analysis identified HIF-1α was a potential USP7-interacting protein in HEK293T cells. B FISH and immunofluorescence assay detected the expressions of USP7 and HIF-1α in lnc-RP11-536 K7.3 knocked out organoids and CR-RKO cell lines and controls. C HIF-1α interacts with USP7. Flag-HIF-1α and Xpress-USP7 plasmids were co-transfected into HEK293T, and the interaction between HIF-1α and USP7 was determined by immunoprecipitation with α-Flag beads (top), or α-Xpress beads (bottom) followed by immunoblotting with α-Xpress or α-Flag antibody. One percent of the whole cell lysates was loaded as input control. D Stability of HIF-1α was reduced by silencing of USP7. Chemo-resistant CC organoids and cells transfected with shUSP7 were treated with cycloheximide, and collected at the indicated times for western blot. E USP7 deubiquitinitiates HIF-1α in cells. Xpress-USP7, Flag-HIF-1α, and HA-Ub plasmids were co-transfected into HEK293T cells. The ubiquitination of precipitated HIF-1α was analyzed by immunoblotting with anti-HA antibody. F USP7 deubiquitinitiates endogenous HIF-1α. Xpress-USP7 plasmids were transfected into HEK293T cells, and ubiquitination of precipitated endogenous HIF-1α was analyzed by immunoblotting with anti-ubiquitin antibody. G Knockdown of USP7 promotes ubiquitination of endogenous HIF-1α. Endogenous HIF-1α was immunoprecipitated from HEK293T-shCtrl or HEK293T-shUSP7 cells pretreated with MG132 (20 μmol/L). The ubiquitination of HIF-1α was analyzed by immunoblotting with anti-ubiquitin antibody. H Knockdown of USP7 promotes ubiquitination of HIF-1α. Flag-HIF-1α and HA-Ub plasmids were co-transfected into HEK293T-shCtrl or HEK293T-shUSP7 cells, and cells were treated with MG132 (20 μmol/L). The ubiquitination of precipitated HIF-1α was analyzed by immunoblotting with anti-ubiquitin antibody. I Knockdown of USP7 promotes degradation of HIF-1α. HEK293T-shUSP7, CR-organoid-shUSP47, CR-RKO-shUSP47 and their controls were treated with or without MG132 (20 μmol/L). The expression levels of USP7, HIF-1α, and actin were detected. Above experiments were repeated 3 times.
Fig. 5 (See legend on previous page.)
endogenous USP7 resulted in a significant decrease in expression level of endogenous HIF-1α in 293T cell lines, CR-organoids, and CR-RKO cell lines, which could be further blocked by MG132 (Fig. 5I). Collectively, the above-mentioned results supported the notion that HIF-1α is a putative substrate of USP7.

**Knockout of Inc-RP11-536 K7.3 inhibited progression of CC and sensitized response to oxaliplatin in vivo**

To further evaluate the effects of Inc-RP11-536 K7.3 on tumorigenesis and chemo-resistance in vivo, Inc-RP11-536 K7.3 knocked out chemo-resistant CC organoids, CR-RKO cell lines, and control groups were then injected subcutaneously into nude mice (Fig. 6A). Mice bearing tumors were randomly grouped with administration of PBS or oxaliplatin. The volume and weight of tumor in the Inc-RP11-536 K7.3 knocked out group were significantly lower than those in the control group regardless of receiving PBS or oxaliplatin treatment (Fig. 6B-D). Of note, differences between Inc-RP11-536 K7.3 knocked out and control groups were noticeably more significant after administration of oxaliplatin compared with those that received PBS. Similarly, positron emission tomography/computed tomography (PET/CT) revealed that tumors derived from the Inc-RP11-536 K7.3 knocked out group exhibited lower mean values of SUVmax than the control group, indicating a reduced glucose uptake (Fig. 6E). The reductions were even more significant under oxaliplatin treatment. The expressions of ALDOA and GLUT1, two essential genes in the glycolysis pathway, were accordingly downregulated after knockout of Inc-RP11-536 K7.3 and the degree of downregulation was more obvious in group of treatment with oxaliplatin (Fig. 6F-G). Subsequently, we performed immunofluorescence in tissues derived from xenograft mice above, and discovered that the expression of SOX2, USP7, and angiogenic marker CD31 were downregulated in mice bearing tumors derived from the Inc-RP11-536 K7.3 knocked out group compared to that in the control group (Fig. 6H-I and Fig. S5A-B). Furthermore, a zebrafish model, a robust model in the study of angiogenesis, was exploited to verify the causal relationship between Inc-RP11-536 K7.3 and vascularization. In addition, knockout of Inc-RP11-536 K7.3 resulted in defective blood vascular patterning, which was especially significant under oxaliplatin treatment (Fig. 6J-K). The above-mentioned results demonstrated that knockout of Inc-RP11-536 K7.3 efficiently sensitized xenografts to oxaliplatin treatment in CC, accompanied by low level of glycolysis and vascular formation.

To establish a clinical relevance in human CC, we analyzed the levels of Inc-RP11-536 K7.3, SOX2, USP7, and HIF-1α in human chemo-resistant and chemo-sensitive CC samples. High expressions of SOX2, USP7, and HIF-1α were detected in the majority of chemo-resistant CC samples, and SOX2 expression was found to positively correlate with the expressions of USP7 and HIF-1α (Fig. 7A-B). Using FISH and immunofluorescence assay, we found that Inc-RP11-536 K7.3 and SOX2 were down-regulated in chemo-sensitive tissues (Fig. 7C). Moreover, we discovered that the expression of SOX2, USP7, HIF-1α and the angiogenic marker CD31 were changed in accordance with Inc-RP11-536 K7.3 expression level both in chemo-resistant and chemo-sensitive human CC tissue sample (Fig. S6A-D). PET/CT revealed that SUVmax value was increased in chemo-resistant CC samples compared to that in chemo-sensitive CC samples (Fig. 7D-E). Besides, SUVmax value was found to positively correlate with Inc-RP11-536 K7.3 expression, and high SUVmax value predicted a poor prognosis (Fig. 7F). Besides that, low expression of CD31 was observed in chemo-resistant CC tissues (Fig. 7G). The schematic model of how Inc-RP11-536 K7.3 participates in oxaliplatin resistance in patient-derived CC organoids and cells was illustrated (Fig. 7H).

**Discussion**

Advanced or metastatic CC patients who develop resistance to oxaliplatin have a poor prognosis and a limited number of therapeutic options [17, 18]. It is therefore meaningful to understand the biological mechanism of resistance to oxaliplatin and identify novel therapeutic targets to enhance chemosensitivity. Moreover, identification of effective biomarkers contributes to the selection of oxaliplatin-responsive patients and realizes clinical benefits. In the current study, patient-derived organoids were exploited to profile molecular network and mimic therapeutic responses in oxaliplatin-resistant or -sensitive organoids of CC patients. Organoids retain...
Fig. 6 (See legend on previous page.)
the genetic and phenotypic stability of their original tissues to a great extent and have a superior predictive ability of patient-specific responses to chemotherapy, highlighting a great promise for personalized therapy [19, 20]. Different from previous studies that employed high-throughput RNA sequencing [21, 22], the present study adopted mass spectrometry-based proteomics to explore the molecular mechanism of oxaliplatin resistance. Ubiquitin-mediated proteolysis, carbon metabolism, and VEGF signaling pathway were identified as novel characteristics of oxaliplatin-resistant organoids of CC patients. This may motivate us to study the mechanism of oxaliplatin resistance from a new perspective. It is noteworthy that lncRNAs are emerging as novel diagnostic, prognostic, and therapeutic targets in CC research compared to protein coding genes [23, 24]. In the present research, we identified a novel lncRNA, Inc-RP11-536 K7.3, to be highly expressed in oxaliplatin-resistant organoids of human CC tissues. To date, no research has concentrated on the functions and regulatory mechanisms of Inc-RP11-536 K7.3. Our data suggested that high expression of Inc-RP11-536 K7.3 in human CC tissues was significantly associated with a poor oxaliplatin response and an inferior prognosis. Therefore, it might be necessary to determine the expression of Inc-RP11-536 K7.3 in CC tissues to identify patients who might benefit more from oxaliplatin treatment before making a clinical decision. Our results revealed that downregulation of Inc-RP11-536 K7.3 could impede CC progression and re-sensitize CC to oxaliplatin treatment both in vitro and in vivo. Hence, we demonstrated that Inc-RP11-536 K7.3 exerted its functions at least partially through modulating glycolysis and angiogenesis. Emerging evidence suggested that chemo-resistant cancer cells exhibited a high level of glycolysis, and targeting glycolysis could be a promising strategy to reverse drug resistance [25–27]. However, the potential mechanisms triggering glycolysis modulation have largely remained elusive. Several molecules have been found to participate in this process [26, 28, 29]. For instance, knockdown of PTBP1 could attenuate the resistance of CC cells to oxaliplatin through regulation of glycolysis [30]. In the present research, we verified the role of Inc-RP11-536 K7.3 in modulating chemosensitivity via glycolysis and vascular remodeling, suggesting that targeting Inc-RP11-536 K7.3 is a promising therapeutic strategy for oxaliplatin-resistant organoids of CC patients in clinical setting. Additionally, lncRNAs have been proposed to regulate local gene expression in cis or leave the site of transcription and perform transcriptional regulation in trans. IncRNA interacting with transcription factors to regulate tumor-related gene expression has been found as a major mechanism in trans [31, 32]. For example, IncRNA HNF1A-AS1 was demonstrated to bind to transcription factor PBX3 to upregulate OTX1 [33]. To elucidate the molecular mechanism of oxaliplatin resistance mediated by Inc-RP11-536 K7.3, RNA pull-down assay in combination with RIP assay was conducted, and SOX2 was identified as an interacting protein. Besides, Inc-RP11-536 K7.3 recruited SOX2 to transcriptionally activate USP7. Intriguingly, Inc-RP11-536 K7.3 not only bound to SOX2 and regulated detection of USP7 promoter, but also affected the expression of SOX2 itself. Therefore, the regulatory effect of Inc-RP11-536 K7.3 on SOX2 transcriptional activity might be a synergetic result of expression modulation, as well as substrate recognition. How Inc-RP11-536 K7.3 can regulate SOX2 expression remains unknown. Studies revealed a positive feedback loop between two transcription factors, SOX2 and SOX6, leading to mutually stimulation of expression [34]. Whether interaction between Inc-RP11-536 K7.3 and SOX2 stimulates SOX6 transcription and forms a positive feedback loop to regulate SOX2 expression should be further investigated. Furthermore, we found that Inc-RP11-536 K7.3 could stabilize HIF-1α by upregulating USP7 expression. USP7, as a deubiquitinating enzyme, could regulate the stability of tumor-associated substrates [35–37]. It was reported that USP7 could activate Wnt signaling pathway and promote tumorigenesis by mediating β-catenin deubiquitination in adenomatous polyposis coli (APC) mutations from colon tumors [38]. In the present research, we identified HIF-1α as a putative substrate of USP7, and we demonstrated that knockdown of USP7 resulted in increased HIF-1α

(See figure on next page.)

**Fig. 7** The expressions of SOX2, USP7, and HIF-1α in chemo-resistant and -sensitive CC tissues and the role of Inc-RP11-536 K7.3 in glucose uptake and angiogenesis. A Representative images of immunohistochemistry of SOX2, USP7, and HIF-1α in CC tissues. B The high expressions of SOX2, USP7, and HIF-1α in 168 oxaliplatin-resistant and 182 oxaliplatin-sensitive human colon cancer tissues. C FISH and immunofluorescence assay were conducted on human chemo-resistant and -sensitive CC tissues. Thirty pairs of human CC tissues were used. D Representative images of PET/CT in human chemo-resistant and -sensitive CC tissues. E-F The relationship between SUVmax value of PET/CT image and Inc-RP11-536 K7.3 expression. 100 colon cancer patients were tested in this experiment. G FISH and immunofluorescence assay were carried out on human chemo-resistant and -sensitive CC tissues. H Schematic illustration of the role of the Inc-RP11-536 K7.3/USP7/HIF-1α signaling axis in regulation of glycolysis, angiogenesis, and sensitivity to oxaliplatin.
Fig. 7 (See legend on previous page.)
ubiquitination and destabilized HIF-1α protein. HIF-1α upregulation has been observed in a variety of human malignant diseases (e.g., CC) [9, 34, 39]. HIF-1α is involved in carcinogenesis, tumor angiogenesis, and cancer progression [40]. Additionally, HIF-1α plays a critical role in drug resistance, and targeting HIF-1α has been reported to significantly attenuate hypoxia-induced oxaliplatin resistance in CC [9].

Conclusion
In summary, a novel lncRNA, lnc-RP11-536K7.3, was identified to upregulate USP7 by recruiting SOX2. Upregulated USP7 deubiquitinates and stabilizes HIF-1α to maintain oxaliplatin resistance and to promote CC progression. Our findings demonstrate that lnc-RP11-536K7.3 plays a crucial role in oxaliplatin resistance, and highlight its significance as a prognostic factor, a predictive indicator for oxaliplatin treatment, and a promising therapeutic target in CC.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13046-021-02143-x.

Additional file 1: Table S1. Association between Inc-RP11-536K7.3 expression and clinicopathological factors in colon cancer TMA (n = 276).

Additional file 2. Supplementary Methods.

Additional file 3: Figure S1. Chemo-resistant and -sensitive organsoid derived from CC patients. (A) Hematoxylin-eosin (HE) staining of oxaliplatin-resistant and -sensitive organsoids of CC tissues. (B) Immunohistochemistry of CK20 and β-catenin in oxaliplatin-resistant and -sensitive organsoids of CC patients.

Additional file 4: Figure S2. Immunohistochemistry staining of human colon cancer markers and the survival analysis of Inc-RP11-536K7.3 in different cancer patients. (A) Immunohistochemistry staining of CK20 and β-catenin in oxaliplatin-resistant and -sensitive human colon cancer tissues. (B) Survival analysis of Inc-RP11-536K7.3 in different cancer patients in TCGA database. (C) The expression of Inc-RP11-536K7.3 in cancer tissues and the adjacent sites in TCGA database.

Additional file 5: Figure S3. Overexpressing Inc-RP11-536K7.3 in the depleted cells/organoids restores glycolysis and angiogenesis. (A-D) Determination of glucose uptake (A), ATP (B), NADPH (C), and lactate production (D) in CC organoids and cells as indicated. Data were presented as mean ± SD of triplicate measurements repeated three times with similar results. Statistical significance was assessed via the Student's t-test (**P < 0.01). (E-F) Measurement of ECAR (E) and OCR (F) in CC organoids and cells as indicated. (G) Statistical analysis of tube formation in different groups (**P < 0.01).

Additional file 6: Figure S4. Effect of Inc-RP11-536K7.3 knockout, SOX2 overexpression on oxaliplatin-sensitivity, glycolysis and angiogenesis in chemo-resistant colon cancer organsoids and cells. (A) Cell viability assay of chemo-resistant colon cancer organsoids and cells treated with 1 μM oxaliplatin in different time intervals. (B) Values of IC50 of oxaliplatin. Colon cancer cells were treated with different concentration of oxaliplatin for 48 h. (C) Relative colony formation efficiency of chemo-resistant colon cancer organsoids and cells treated with or without 2 μM oxaliplatin for 7 days. (D) Determination of glucose uptake, ATP, NADPH and lactate production as described in Methods. Data are means ± SD of triplicate measurements repeated 3 times with similar results. Statistical significance was assessed with two-tailed Student's t test. (E-F) ECAR (E) and OCR (F) were determined as described in Methods.

Additional file 7: Figure S5. Immunofluorescence assay of nude mice transplanted tumor tissues. (A) Immunofluorescence assay indicated the association between SOX2 and USP7 in nude mice transplanted tumor tissues. (B) Immunofluorescence assay indicated the association between SOX2 and CD31 in nude mice transplanted tumor tissues.

Additional file 8: Figure S6. Immunofluorescence assay of human colon cancer tissues. (A) Immunofluorescence assay indicated the association between SOX2 and USP7 in Inc-RP11-536K7.3 high expressed chemoresistant colon cancer tissues and Inc-RP11-536K7.3 low expressed chemoresistant colon cancer samples. (B) Immunofluorescence assay indicated the association between SOX2 and HIF-1α in Inc-RP11-536K7.3 high expressed chemo-resistant colon cancer tissues and Inc-RP11-536K7.3 low expressed chemo-sensitive colon cancer samples. (C) Immunofluorescence assay indicated the association between SOX2 and CD31 in Inc-RP11-536K7.3 high expressed chemoresistant colon cancer tissues and Inc-RP11-536K7.3 low expressed chemoresistant colon cancer samples. (D) Immunofluorescence assay indicated the association between SOX2 and CD31 in Inc-RP11-536K7.3 high expressed chemoresistant colon cancer tissues and Inc-RP11-536K7.3 low expressed chemoresistant colon cancer samples.

Acknowledgments
Not applicable.

Authors' contributions
ZLW, QGL and YL designed the experiment. QGL, HZS, DKL and JL performed the experiments. LG, SBM, YFY and MDX performed the data analysis. HZS, ZLW, QGL and YL designed the experiment. QGL, HZS, DKL and JL performed the experiments. LG, SBM, YFY and MDX performed the data analysis. HZS, ZLW, QGL and YL designed the experiment. QGL, HZS, DKL and JL performed the experiments. LG, SBM, YFY and MDX performed the data analysis. HZS, ZLW, QGL and YL designed the experiment. QGL, HZS, DKL and JL performed the experiments. LG, SBM, YFY and MDX performed the data analysis. HZS, ZLW, QGL and YL designed the experiment. QGL, HZS, DKL and JL performed the experiments. LG, SBM, YFY and MDX performed the data analysis. HZS, ZLW, QGL and YL designed the experiment. QGL, HZS, DKL and JL performed the experiments. LG, SBM, YFY and MDX performed the data analysis. HZS, ZLW, QGL and YL designed the experiment. QGL, HZS, DKL and JL performed the experiments. LG, SBM, YFY and MDX performed the data analysis. HZS, ZLW, QGL and YL designed the experiment. QGL, HZS, DKL and JL performed the experiments. LG, SBM, YFY and MDX performed the data analysis.

Funding
This work was supported by National Natural Science Foundation of China (81872117) for Ziliang Wang and (81772599 and 81972260) for Xinxiang Li, by National Science Foundation of China (81802370) and Shanghai Sailing Program (18YF140420) for Lu Gan.

Availability of data and materials
For all data requests, please contact the corresponding author.

Declarations
Ethics approval and consent to participate
This study was approved by the Medical Ethics Committee of Fudan University Shanghai Cancer Center (ID 050432–4-1911D).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin United States. 2021;71:209–49.

2. Rodel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol England. 2012;13:1021–30.

3. Shi Y, Li H, Zhang Y, Chen X, Guo Y, Cao J, et al. Long non-coding RNA LINC00651 promotes colorectal cancer through regulation of glycolysis. Biomed Pharmacother. 2020;124:110669.

4. Guo P, Chen X, Xie R, Han J, Xie W, Wang B, et al. IncRNA HOXD-AS1 regulates proliferation and chemo-resistance of castration-resistant prostate cancer via recruiting WDR5. Mol Ther. 2017;25:1959–73.

5. Vyas R, Guo Y, Cao X-L, Yang H, Cui J, Li Z-J, et al. GOLPH3 inhibition reverses chemoresistance of colorectal cancer cells through regulation of anaplastic lymphoma kinase (ALK). Cancer Cell United States. 2020;38:228–43.e8.

6. Gu J, Wang X, Zhang D, Li Y, Deng T, et al. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance of CRC cells. Cell Death Differ. 2020;27:1316–27.
35. Luo M, Zhou J, Leu NA, Abreu CM, Wang J, Anguera MC, et al. Polycomb protein SCML2 associates with USP7 and counteracts histone H2A ubiquitination in the XY chromatin during male meiosis. PLoS Genet. 2015;11:e1004954.

36. Lee JE, Park CM, Kim JH. USP7 deubiquitinates and stabilizes EZH2 in prostate cancer cells. Genet Mol Biol. 2020;43:e20190338.

37. He Y, Wang S, Tong J, Jiang S, Yang Y, Zhang Z, et al. The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival. J Biol Chem. 2020;295:2084–96.

38. Novellasdemunt L, Foglizzo V, Cuadrado L, Antas P, Kucharska A, Encheva V, et al. USP7 is a tumor-specific WNT activator for APC-mutated colorectal cancer by mediating β-catenin Deubiquitination. Cell Rep. 2017;21:612–27.

39. Lin M-C, Lin J-J, Hsu C-L, Juan H-F, Lou P-J, Huang M-C. GATA3 interacts with and stabilizes HIF-1α to enhance cancer cell invasiveness. Oncogene. 2017;36:4243–52.

40. Ioannou M, Paraskeva E, Baxevanidou K, Simos G, Papamichali R, Papachalaralambous C, et al. HIF-1α in colorectal carcinoma: review of the literature. J BUON Greece. 2015;20:680–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.